Searched for
PHARMA FIRM LICENSES
Stocks in news: Sun Pharma, Tech Mahindra, Tata Motors, Voltas, ONGCIndian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...- Stocks in news: ITC, LIC, Sun Pharma, Maruti Suzuki, Fino Payments BankBenchmark indices experienced a negative close on Thursday, marked by volatile trade and profit booking. Analysts anticipate the Nifty to c...
- Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked targetCipla shares surged on Thursday, extending gains to nearly 11% in two sessions, after several brokerages turned bullish on the stock despit...
- Tata group’s Impetis out-licenses arthritis and autoimmune drugs to VyomeIn a significant move for medical innovation, Impetis Biosciences, a subsidiary of Tata group, has teamed up with Vyome Holdings from the U...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Sun Pharma to acquire Organon for $11.75 billion in India’s biggest pharma dealSun Pharma, led by Dilip Shanghvi, has agreed to acquire US-based Organon in an all-cash deal worth $11.75 billion, marking the largest acq...
- Sun Pharma deal structurally strong, debt the only overhang: Amit KhuranaMarket expert Amit Khurana offers insights on key corporate and regulatory developments. Sun Pharma's acquisition is seen as strategically ...
- Mankind Pharma scouts for M&A deals to boost local branded bizMankind Pharma, the fourth-largest pharmaceutical company in India, led by Rajeev Juneja, is seeking mergers, acquisitions, and in-licensin...
- Aurobindo Pharma arm signs pact with Medicines Patent Pool to develop anti-cancer drugIndia's Aurobindo Pharma has announced that its subsidiary Eugia Pharma Specialities has signed a voluntary sub-licensing agreement with Me...
- Licences of 18 pharma companies cancelled for manufacturing spurious drugs"Licences of 18 pharma companies have been cancelled for manufacturing spurious and adulterated drugs and for violating GMP (good manufactu...
- Dr Reddy’s inks licensing pact with Gilead for Remdesivir to treat Covid-19The Hyderabad headquartered drug maker will obtain technology transfer from Gilead for manufacturing of the drug wherein the Indian firm wo...
- Sun Pharma, US-based Rockwell Medical enter into licensing pact for Triferic in IndiaAs per the terms of the agreement, Sun Pharma will be the exclusive development and commercialisation partner for Triferic during the term ...
- Sun Pharma rises after licensing deal with AlmirallAt 11:01 am, shares of the company were trading at Rs 817.80 per share, up 1.24 per cent from its previous close on the Bombay Stock Exchan...
- Patent not to affect hepatitis C drug price in India: Gilead Sciences Inc"It is the company's goal to enable access to these medicines for as many people as possible, as quickly as possible," the spokesperson add...
- Two generics makers end battle to copy drugs amid patent debateBoth companies, BDR Pharma and Lee Pharma, had been seeking so-called compulsory licenses that override patents and allow generics firms in...
- Anti-diabetes Molecules: Connexios inks licence deal with German pharma major Boehringer IngelheimFor Connexios, this sale of its anti-diabetes molecules to Boehringer Ingelheim is the first out-licensing deal by an Indian life-sciences ...
- Pharma industry split over nod to Natco to sell Bayer's cancer drugThe decision to allow Natco Pharma to sell Bayer's patented cancer drug Nexavar has divided the pharmaceutical industry.
- Pharma sector gains from Re appreciationThe appreciation of the rupee might have brought in its share of woes for exporters and traders alike, but for the pharmaceutical sector wi...
- Claris Lifesciences makes inroads into GermanyClaris Lifesciences, which recently attracted investment from leading international pharma group Carlyle, has formally made inroads into th...
- Licensing ops galore for pharma cosIndian pharma companies that are into R&D can take heart from this bit of statistic.
Load More
